Related Experiment Video
Updated: Mar 22, 2026
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Serum Fractalkine (CX3CL1) Concentration Correlates with Clinical Severity in Pediatric Atopic Dermatitis Patients
Shubin Chong1, Haimei Lan2, Kang Zeng2
1Department of Dermatology, Nan Hai Hospital affliated to Southern Medical University, China csb198198@126.com.
Insights
Elevated fractalkine (FKN) levels are found in children with atopic dermatitis (AD) and correlate with disease severity. FKN may be a useful biomarker for assessing AD in pediatric patients.
Area of Science:
- Immunology
- Dermatology
- Allergy Research
Background:
- Atopic dermatitis (AD) is a prevalent childhood inflammatory skin condition.
- Elevated fractalkine (FKN) expression is observed in individuals with AD.
Purpose of the Study:
- To determine serum fractalkine (FKN) levels in pediatric atopic dermatitis (AD) patients.
- To assess the relationship between FKN levels and AD disease severity.
Main Methods:
- Serum samples from 57 AD children and 53 healthy controls were analyzed.
- Disease severity was evaluated using scoring systems (LSS, SSS, SCORAD).
- Serum FKN, IgE, and IL-31 levels were measured; FKN was re-assessed post-treatment.
Main Results:
- Serum FKN levels were significantly higher in AD children compared to healthy controls, during both flare and quiescent states.
- FKN levels positively correlated with all assessed disease severity scores (LSS, SSS, SCORAD).
- Serum FKN levels also showed a positive correlation with immunoglobulin E (IgE) and interleukin-31 (IL-31) levels.
Conclusions:
- Fractalkine (FKN) shows potential as a reliable biomarker for assessing atopic dermatitis (AD) severity in children.
- Further research into therapeutic strategies targeting FKN for AD treatment is warranted.
Background:
Atopic dermatitis (AD) is a common inflammatory allergic disease presenting pruritic skin lesions mainly in early childhood. Elevated fractalkine (FKN) expression is detected in AD patients.
Objective:
We aimed to investigate the levels of FKN in serum and their association with disease severity in pediatric AD patients.
Methods:
Serum samples were obtained from 57 AD children and 53 healthy children. Disease severity was assessed according to the following scoring systems: Leicester sign score (LSS), simple scoring system of costa (SSS), SCORing atopic dermatitis (SCORAD) index, and objective SCORAD. Serum FKN levels were measured using a sandwich enzyme-linked immunosorbent assay. Serum levels of immunoglobulin (Ig) E and interleukin (IL)-31 and the association of serum FKN levels with the scoring systems as well as IgE and IL-31 levels were evaluated. The FKN levels were re-assessed after symptomatic relief.
Results:
Serum FKN levels in AD children during both flare and quiescence episodes were significantly higher than in the healthy individuals. Additionally, these correlated positively with all disease severity related scoring systems and serum IgE and IL-31 levels.
Conclusions:
FKN may serve as a reliable biomarker for evaluating disease severity in AD patients. Therapeutic interventions for AD, targeting FKN, deserve further study.
